Conference Reports for NATAP

Back

International Workshop on Antiviral Drug Resistance June 3-7 2014, Berlin, Germany     TAF Potency vs TDF-Resistant Virus - Limited Evolution of Tenofovir-Resistant Viruses after Extended TAF Resistance Selection - (04/20/15)   Antiviral Activity of Tenofovir Alafenamide (TAF) against Major NRTI-Resistant Viruses: Improvement over TDF/TFV is Driven by Higher TFV-DP Loading in Target Cells - (04/20/15)   HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Primary Week 24 Analysis of Emergent Drug Resistance - (06/09/13)   The Prevalence of HCV NS5A, Nucleoside and Protease Inhibitor Resistance Associated Variants and the Effects on Treatment with Ledipasvir/Sofosbuvir ± RBV in the Phase 3 ION Studies (06/09/13)   Persistence of Resistance-Associated Variants in Hepatitis C Virus (HCV) Genotype 1-4 Infected Subjects Following 3-day Samatasvir Monotherapy (06/09/13)   Doravirine (MK-1439): A Novel HIV-1 NNRTI With a Distinct Resistance Profile (06/06/13)   Raltegravir (RAL) Resistant Isolates without Primary RAL Integrase (IN) Mutations are Cross-resistant to Elvitegravir (EVG) but not Dolutegravir (DTG) (06/06/13)   An Analysis of Minor Variants in HIV-1 Integrase (IN) for Subjects With Only Historic Evidence of Integrase Inhibitor (INI) Resistance Enrolled in Study ING112574 (VIKING-3) (slide presentation, poster to follow) (06/06/13)   Excellent Virological and Immunological Response to Dolutegravir despite Extensive RT, PR and INI Resistance (06/06/13)